Diagnostik und Therapie der Großgefäßvaskulitiden – Wo stehen wir aktuell?

Zusammenfassung

Die beiden Großgefäßvaskulitiden unterscheiden sich in mehrfacher Hinsicht, vor allem aber durch das Alter der betroffenen Patienten bei Erstmanifestation. Die Riesenzellarteriitis (RZA) ist eine Erkrankung des älteren Patienten wohingegen die Takayasu Arteriitis per definitionem vor dem 40 Lebensjahr auftritt. Die Diagnosen sind in den letzten Jahren durch verbesserte Bildgebung und Therapieoptionen mehr ins Bewusstsein gerückt. Neben der klassischen Steroidtherapie – welche bis heute Mittel der ersten Wahl ist – steht uns mit Tocilizumab, einem monoklonalen Antikörper gegen IL6-Rezeptor, zumindest für die RZA, eine zusätzliche hocheffektive Therapie zur Verfügung. Andere vielversprechende Substanzen befinden sich derzeit in Erprobung. Dieser Artikel soll einen Überblick zu Diagnostik und Therapie, aber auch einen Ausblick zu möglicherweise kommenden medikamentösen Optionen bieten.

Abstract

The two forms of large vessel vasculitis differ in a number of ways, but mainly in patient age at first manifestation. Giant cell arteritis (GCA) is a disease of the elderly patient whereas Takayasu arteritis by definition occurs before the age of 40. The diagnoses have gained more awareness in recent years due to improved imaging and treatment options. Besides the classical steroid therapy – which is still the first choice – Tocilizumab, a monoclonal antibody against the IL-6 receptor, provides an additional, highly effective option, at least for the treatment of GCA. Other promising substances are currently being tested. This article aims to provide an overview of diagnostics and therapy, but also an outlook on possible upcoming drug options.

Schlüsselwörter

Großgefäßvaskulitis - Riesenzellarteriitis - Takayasu Arteriitis - Therapie

Key words

Takayasu arteritis - therapy - large vessel vasculitis - giant cell arteritisonline publiziert 2022

Publication History

Article published online:
02 November 2022

• Literatur

• 1 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11 DOI: 10.1002/art.37715.
• 2 Pugh D, Karabayas M, Basu N. et al. Large-vessel vasculitis. Nat Rev Dis Primers 2022; 7: 93 DOI: 10.1038/s41572-021-00327-5.
• 3 Goel R, Gribbons KB, Carette S. et al. Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America. Rheumatology (Oxford) 2020; 59: 1118-1127 DOI: 10.1093/rheumatology/kez421.
• 4 Quinn KA, Gribbons KB, Carette S. et al. Patterns of clinical presentation in Takayasu’s arteritis. Semin Arthritis Rheum 2020; 50: 576-581 DOI: 10.1016/j.semarthrit.2020.04.012.
• 5 Dejaco C, Ramiro S, Duftner C. et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 77: 636-643 DOI: 10.1136/annrheumdis-2017-212649.
• 6 Gribbons KB, Ponte C, Craven A. et al. Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. Arthritis Rheumatol 2020; 72: 667-676 DOI: 10.1002/art.41165.
• 7 Dasgupta B, Cimmino MA, Kremers HM. et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943-954 DOI: 10.1002/art.34356.
• 8 Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-245 DOI: 10.1016/S0140-6736(08)61077-6.
• 9 Nielsen AW, Frolund LL, Vaben C. et al. Concurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis. Semin Arthritis Rheum 2022; 56: 152069 DOI: 10.1016/j.semarthrit.2022.152069.
• 10 Arend WP, Michel BA, Bloch DA. et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-1134 DOI: 10.1002/art.1780330811.
• 11 Hunder GG, Bloch DA, Michel BA. et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-1128 DOI: 10.1002/art.1780330810.
• 12 Betrains A, Blockmans D. Diagnostic Approaches for Large Vessel Vasculitides. Open Access Rheumatol 2021; 13: 153-165 DOI: 10.2147/OARRR.S282605.
• 13 Schirmer JH, Aries PM, Balzer K. et al. S2k guidelines: management of large-vessel vasculitis. Z Rheumatol 2020; 79: 67-95 DOI: 10.1007/s00393-020-00893-1.
• 14 Hellmich B, Agueda A, Monti S. et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79: 19-30 DOI: 10.1136/annrheumdis-2019-215672.
• 15 Andel PM, Chrysidis S, Geiger J. et al. Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. Rheumatology (Oxford) 2021; 60: 4958-4971 DOI: 10.1093/rheumatology/keab547.
• 16 Luqmani R, Lee E, Singh S. et al. The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess 2016; 20: 1-238 DOI: 10.3310/hta20900.
• 17 de Franciscis S, Serra R, Luongo A. et al. The management of Takayasu’s arteritis: personal experience. Ann Vasc Surg 2007; 21: 754-760 DOI: 10.1016/j.avsg.2007.03.021.
• 18 Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48: 658-661 DOI: 10.1136/ard.48.8.658.
• 19 Matsuura K, Ogino H, Kobayashi J. et al. Surgical treatment of aortic regurgitation due to Takayasu arteritis: long-term morbidity and mortality. Circulation 2005; 112: 3707-3712 DOI: 10.1161/CIRCULATIONAHA.105.535724.
• 20 Stone JH, Tuckwell K, Dimonaco S. et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317-328 DOI: 10.1056/NEJMoa1613849.
• 21 Mahr AD, Jover JA, Spiera RF. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-2797 DOI: 10.1002/art.22754.
• 22 Koster MJ, Yeruva K, Crowson CS. et al. Efficacy of Methotrexate in Real-world Management of Giant Cell Arteritis: A Case-control Study. J Rheumatol 2019; 46: 501-508 DOI: 10.3899/jrheum.180429.
• 23 Alba MA, Garcia-Martinez A, Prieto-Gonzalez S. et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014; 93: 194-201 DOI: 10.1097/MD.0000000000000033.
• 24 Henes J. How long should treatment with tocilizumab be carried out for giant cell arteritis and how should it be ended (discontinue/taper off)?. Z Rheumatol 2021; 80: 176-179 DOI: 10.1007/s00393-020-00947-4.
• 25 de Souza AW, de Almeida Agustinelli R, de Cinque Almeida H. et al. Leflunomide in Takayasu arteritis – A long term observational study. Rev Bras Reumatol 2016; DOI: 10.1016/j.rbr.2015.09.007.
• 26 Barra L, Yang G, Pagnoux C. et al. Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: A systematic review and meta-analysis. Autoimmun Rev 2018; 17: 683-693 DOI: 10.1016/j.autrev.2018.01.019.
• 27 Misra DP, Wakhlu A, Agarwal V. et al. Recent advances in the management of Takayasu arteritis. Int J Rheum Dis 2019; 22: 60-68 DOI: 10.1111/1756-185X.13285.
• 28 Hoffman GS, Leavitt RY, Kerr GS. et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-582 DOI: 10.1002/art.1780370420.
• 29 Langford CA, Cuthbertson D, Ytterberg SR. et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 2017; 69: 846-853 DOI: 10.1002/art.40037.
• 30 Nakaoka Y, Isobe M, Takei S. et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018; 77: 348-354 DOI: 10.1136/annrheumdis-2017-211878.
• 31 Alibaz-Oner F, Kaymaz-Tahra S, Bayindir O. et al. Biologic treatments in Takayasu’s Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab. Semin Arthritis Rheum 2021; 51: 1224-1229 DOI: 10.1016/j.semarthrit.2021.09.010.
• 32 Mekinian A, Biard L, Dagna L. et al. Efficacy and safety of TNF-alpha antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford) 2022; 61: 1376-1384 DOI: 10.1093/rheumatology/keab635.
• 33 de Souza AW, Machado NP, Pereira VM. et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010; 74: 1236-1241 DOI: 10.1253/circj.cj-09-0905.
• 34 Kwon OC, Oh JS, Park MC. et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol 2019; 287: 111-115 DOI: 10.1016/j.ijcard.2019.02.046.
• 35 Jeong HS, Jung JH, Song GG. et al. Endovascular balloon angioplasty versus stenting in patients with Takayasu arteritis: A meta-analysis. Medicine (Baltimore) 2017; 96: e7558 DOI: 10.1097/MD.0000000000007558.
• 36 Nicholas WJ, Maloney TG. Drug-Coated Balloon Angioplasty for Thoracic Great Vessel Stenosis Due to Takayasu Arteritis With 1-Year Follow-up. J Endovasc Ther 2022; 15266028221105180 DOI: 10.1177/15266028221105180.
• 37 Schmidt WA, Dasgupta B, Luqmani R. et al. A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. Rheumatol Ther 2020; 7: 793-810 DOI: 10.1007/s40744-020-00227-2.
• 38 Gon Y, Yoshifuji H, Nakajima T. et al. Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol 2021; 31: 678-683 DOI: 10.1080/14397595.2020.1800560.
• 39 Saur SJ, Horger M, Henes J. Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis. Rheumatol Adv Pract 2021; 5 rkaa082 DOI: 10.1093/rap/rkaa082.
• 40 Terao C, Yoshifuji H, Nakajima T. et al. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol 2016; 45: 80-82 DOI: 10.3109/03009742.2015.1060521.
• 41 Yoshifuji H, Terao C. Roles of cytotoxic lymphocytes and MIC/LILR families in pathophysiology of Takayasu arteritis. Inflamm Regen 2020; 40: 9 DOI: 10.1186/s41232-020-00119-6.
• 42 Venhoff N, Schmidt WA, Lamprecht P. et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials 2021; 22: 543 DOI: 10.1186/s13063-021-05520-1.
• 43 Venhoff N. Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial. Arthritis Rheum 2021; 73
• 44 Rathore U, Thakare DR, Patro P. et al. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 2022; 41: 33-44 DOI: 10.1007/s10067-021-05973-4.
• 45 Kong X, Sun Y, Dai X. et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 2022; 81: 117-123 DOI: 10.1136/annrheumdis-2021-220832.
• 46 Wang J, Dai X, Ma L. et al. Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. Semin Arthritis Rheum 2022; 55: 152018 DOI: 10.1016/j.semarthrit.2022.152018.